Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 39167807

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2024 Aug 22
First author
Choueiri TK

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2024 Nov 28;391(21):2061-2062. doi: 10.1056/NEJMc2411843.
    note
    Source null
    related pmid
    39602644
    relationship
    Comment in
  2. citation
    N Engl J Med. 2024 Nov 28;391(21):2062-2063. doi: 10.1056/NEJMc2411843.
    note
    Source null
    related pmid
    39602645
    relationship
    Comment in

Authors and identifiers

  1. name
    Choueiri TK
    type
    Author
  2. name
    Powles T
    type
    Author
  3. name
    Peltola K
    type
    Author
  4. name
    de Velasco G
    type
    Author
  5. name
    Burotto M
    type
    Author
  6. name
    Suarez C
    type
    Author
  7. name
    Ghatalia P
    type
    Author
  8. name
    Iacovelli R
    type
    Author
  9. name
    Lam ET
    type
    Author
  10. name
    Verzoni E
    type
    Author
  11. name
    Gümüş M
    type
    Author
  12. name
    Stadler WM
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Choueiri TK
    type
    Author
  2. name
    Powles T
    type
    Author
  3. name
    Peltola K
    type
    Author
  4. name
    de Velasco G
    type
    Author
  5. name
    Burotto M
    type
    Author
  6. name
    Suarez C
    type
    Author
  7. name
    Ghatalia P
    type
    Author
  8. name
    Iacovelli R
    type
    Author
  9. name
    Lam ET
    type
    Author
  10. name
    Verzoni E
    type
    Author
  11. name
    Gümüş M
    type
    Author
  12. name
    Stadler WM
    type
    Author
bibliography ids
  1. nci-bib-fbff02902dabffd4e97af223
book metadata
content sha256
acad5198a88c99eaaae8f1b4c17f97fd486d4e5b6a4144a8218f29ee82645357
document type
citation
dois
  1. 10.1056/NEJMoa2313906
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:39167807
immutable id
pubmed:39167807@acad5198a88c99eaaae8f1b4c17f97fd486d4e5b6a4144a8218f29ee82645357
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
8
name
The New England journal of medicine
nlm unique id
0255562
pages
710-721
volume
391
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2024 Nov 28;391(21):2061-2062. doi: 10.1056/NEJMc2411843.
    note
    Source null
    related pmid
    39602644
    relationship
    Comment in
  2. citation
    N Engl J Med. 2024 Nov 28;391(21):2062-2063. doi: 10.1056/NEJMc2411843.
    note
    Source null
    related pmid
    39602645
    relationship
    Comment in
outcomes validated
false
pmid
39167807
provenance
batch id
3e43afde6f26fc8df6da
provider
NCBI PubMed ESummary
record sha256
eb6c54a3febe46d514c6e585ca1b9a97ef1562958a2f1bae2b06946616eda75b
response sha256
fa51c3b310a444d84ada833c4cda53c9e4e97161ab5048020b99c51e56e843d2
retrieved at
2026-09-09T23:48:21.145285+00:00
publication date
display
2024 Aug 22
precision
day
year
2024
publication types
  1. Journal Article
  2. Clinical Trial, Phase III
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Comparative Study
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/39167807/
title
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.

Preserved source evidence · Not medical advice